<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6.	ADVERSE REACTIONS<BR>               <BR>                  Of the CELEBREX-treated patients in the pre-marketing controlled clinical trials, approximately 4,250 were patients with OA, approximately 2,100 were patients with RA, and approximately 1,050 were patients with post-surgical pain. More than 8,500 patients received a total daily dose of CELEBREX of 200 mg (100 mg twice daily or 200 mg once daily) or more, including more than 400 treated at 800 mg (400 mg twice daily). Approximately 3,900 patients received CELEBREX at these doses for 6 months or more; approximately 2,300 of these have received it for 1 year or more and 124 of these have received it for 2 years or more.<BR>                  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        Most common adverse reactions in arthritis trials (>2% and >placebo): abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, rash  (6.1). <BR>                         <BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.1 Pre-marketing Controlled Arthritis Trials<BR>                     <BR>                        Table 1 lists all adverse events, regardless of causality, occurring in ≥2% of patients receiving CELEBREX from 12 controlled studies conducted in patients with OA or RA that included a placebo and/or a positive control group. Since these 12 trials were of different durations, and patients in the trials may not have been exposed for the same duration of time, these percentages do not capture cumulative rates of occurrence.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="table1" width="100%"><BR>                           <caption>Table 1:  Adverse Events Occurring in &#8805;2% of CELEBREX Patients from Pre-marketing Controlled Arthritis Trials</caption><BR>                           <col align="left" valign="top" width="25%"/><BR>                           <col align="center" valign="top" width="15%"/><BR>                           <col align="center" valign="top" width="15%"/><BR>                           <col align="center" valign="top" width="15%"/><BR>                           <col align="center" valign="top" width="15%"/><BR>                           <col align="center" valign="top" width="15%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th styleCode="Lrule Rrule"/><BR>                                 <th styleCode="Rrule">CBX<br/>N=4146</th><BR>                                 <th styleCode="Rrule">Placebo<br/>N=1864</th><BR>                                 <th styleCode="Rrule">NAP<br/>N=1366</th><BR>                                 <th styleCode="Rrule">DCF<br/>N=387</th><BR>                                 <th styleCode="Rrule">IBU<br/>N=345</th><BR>                              </tr><BR>                           </thead><BR>                           <tfoot><BR>                              <tr><BR>                                 <td colspan="6" align="left">CBX = CELEBREX 100 &#8211; 200 mg twice daily or 200 mg once daily;<br/>NAP = Naproxen 500 mg twice daily;<br/>DCF = Diclofenac 75 mg twice daily;<br/>IBU = Ibuprofen 800 mg three times daily.</td><BR>                              </tr><BR>                           </tfoot><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Gastrointestinal</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Abdominal Pain</td><BR>                                 <td styleCode="Rrule">4.1%</td><BR>                                 <td styleCode="Rrule">2.8%</td><BR>                                 <td styleCode="Rrule">7.7%</td><BR>                                 <td styleCode="Rrule">9.0%</td><BR>                                 <td styleCode="Rrule">9.0%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Diarrhea</td><BR>                                 <td styleCode="Rrule">5.6%</td><BR>                                 <td styleCode="Rrule">3.8%</td><BR>                                 <td styleCode="Rrule">5.3%</td><BR>                                 <td styleCode="Rrule">9.3%</td><BR>                                 <td styleCode="Rrule">5.8%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Dyspepsia</td><BR>                                 <td styleCode="Rrule">8.8%</td><BR>                                 <td styleCode="Rrule">6.2%</td><BR>                                 <td styleCode="Rrule">12.2%</td><BR>                                 <td styleCode="Rrule">10.9%</td><BR>                                 <td styleCode="Rrule">12.8%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Flatulence</td><BR>                                 <td styleCode="Rrule">2.2%</td><BR>                                 <td styleCode="Rrule">1.0%</td><BR>                                 <td styleCode="Rrule">3.6%</td><BR>                                 <td styleCode="Rrule">4.1%</td><BR>                                 <td styleCode="Rrule">3.5%</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Nausea</td><BR>                                 <td styleCode="Rrule">3.5%</td><BR>                                 <td styleCode="Rrule">4.2%</td><BR>                                 <td styleCode="Rrule">6.0%</td><BR>                                 <td styleCode="Rrule">3.4%</td><BR>                                 <td styleCode="Rrule">6.7%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Body as a whole</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Back Pain</td><BR>                                 <td styleCode="Rrule">2.8%</td><BR>                                 <td styleCode="Rrule">3.6%</td><BR>                                 <td styleCode="Rrule">2.2%</td><BR>                                 <td styleCode="Rrule">2.6%</td><BR>                                 <td styleCode="Rrule">0.9%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Peripheral Edema</td><BR>                                 <td styleCode="Rrule">2.1%</td><BR>                                 <td styleCode="Rrule">1.1%</td><BR>                                 <td styleCode="Rrule">2.1%</td><BR>                                 <td styleCode="Rrule">1.0%</td><BR>                                 <td styleCode="Rrule">3.5%</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Injury-Accidental</td><BR>                                 <td styleCode="Rrule">2.9%</td><BR>                                 <td styleCode="Rrule">2.3%</td><BR>                                 <td styleCode="Rrule">3.0%</td><BR>                                 <td styleCode="Rrule">2.6%</td><BR>                                 <td styleCode="Rrule">3.2%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Central, Peripheral Nervous system</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Dizziness</td><BR>                                 <td styleCode="Rrule">2.0%</td><BR>                                 <td styleCode="Rrule">1.7%</td><BR>                                 <td styleCode="Rrule">2.6%</td><BR>                                 <td styleCode="Rrule">1.3%</td><BR>                                 <td styleCode="Rrule">2.3%</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Headache</td><BR>                                 <td styleCode="Rrule">15.8%</td><BR>                                 <td styleCode="Rrule">20.2%</td><BR>                                 <td styleCode="Rrule">14.5%</td><BR>                                 <td styleCode="Rrule">15.5%</td><BR>                                 <td styleCode="Rrule">15.4%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Psychiatric</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Insomnia</td><BR>                                 <td styleCode="Rrule">2.3%</td><BR>                                 <td styleCode="Rrule">2.3%</td><BR>                                 <td styleCode="Rrule">2.9%</td><BR>                                 <td styleCode="Rrule">1.3%</td><BR>                                 <td styleCode="Rrule">1.4%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Respiratory</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Pharyngitis</td><BR>                                 <td styleCode="Rrule">2.3%</td><BR>                                 <td styleCode="Rrule">1.1%</td><BR>                                 <td styleCode="Rrule">1.7%</td><BR>                                 <td styleCode="Rrule">1.6%</td><BR>                                 <td styleCode="Rrule">2.6%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Rhinitis</td><BR>                                 <td styleCode="Rrule">2.0%</td><BR>                                 <td styleCode="Rrule">1.3%</td><BR>                                 <td styleCode="Rrule">2.4%</td><BR>                                 <td styleCode="Rrule">2.3%</td><BR>                                 <td styleCode="Rrule">0.6%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Sinusitis</td><BR>                                 <td styleCode="Rrule">5.0%</td><BR>                                 <td styleCode="Rrule">4.3%</td><BR>                                 <td styleCode="Rrule">4.0%</td><BR>                                 <td styleCode="Rrule">5.4%</td><BR>                                 <td styleCode="Rrule">5.8%</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Upper Respiratory Infection</td><BR>                                 <td styleCode="Rrule">8.1%</td><BR>                                 <td styleCode="Rrule">6.7%</td><BR>                                 <td styleCode="Rrule">9.9%</td><BR>                                 <td styleCode="Rrule">9.8%</td><BR>                                 <td styleCode="Rrule">9.9%</td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Skin</content><BR>                                 </td><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                                 <td styleCode="Rrule"/><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Lrule Rrule">&#160;&#160;Rash</td><BR>                                 <td styleCode="Rrule">2.2%</td><BR>                                 <td styleCode="Rrule">2.1%</td><BR>                                 <td styleCode="Rrule">2.1%</td><BR>                                 <td styleCode="Rrule">1.3%</td><BR>                                 <td styleCode="Rrule">1.2%</td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>In placebo- or active-controlled clinical trials, the discontinuation rate due to adverse events was 7.1% for patients receiving CELEBREX and 6.1% for patients receiving placebo. Among the most common reasons for discontinuation due to adverse events in the CELEBREX treatment groups were dyspepsia and abdominal pain (cited as reasons for discontinuation in 0.8% and 0.7% of CELEBREX patients, respectively). Among patients receiving placebo, 0.6% discontinued due to dyspepsia and 0.6% withdrew due to abdominal pain.<BR>                     <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 The following adverse reactions occurred in 0.1 – 1.9% of patients treated with CELEBREX (100 – 200 mg twice daily or 200 mg once daily):<BR>                              <BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%" ID="iaea305c4-79da-415f-806e-884c941f0a19"><BR>                                 <col align="left" valign="top" width="25%"/><BR>                                 <col align="left" valign="top" width="75%"/><BR>                                 <tbody><BR>                                    <tr styleCode="toprule"><BR>                                       <td><BR>                                          <content styleCode="bold italics">Gastrointestinal</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Constipation, diverticulitis, dysphagia, eructation, esophagitis, gastritis, gastroenteritis, gastroesophageal reflux, hemorrhoids, hiatal hernia, melena, dry mouth, stomatitis, tenesmus, vomiting</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Cardiovascular:</content><BR>                                       </td><BR>                                       <td>Aggravated hypertension, angina pectoris, coronary artery disorder, myocardial infarction</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">General</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Allergy aggravated, allergic reaction, chest pain, cyst NOS, edema generalized, face edema, fatigue, fever, hot flushes, influenza-like symptoms, pain, peripheral pain</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Central, peripheral nervous system:</content><BR>                                       </td><BR>                                       <td>Leg cramps, hypertonia, hypoesthesia, migraine, paresthesia, vertigo</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Hearing and vestibular</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Deafness, tinnitus</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Heart rate and rhythm</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Palpitation, tachycardia</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Liver and biliary</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Hepatic function abnormal, SGOT increased, SGPT increased</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Metabolic and nutritional</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>BUN increased, CPK increased, hypercholesterolemia, hyperglycemia, hypokalemia, NPN increased, creatinine increased, alkaline phosphatase increased, weight increased</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Musculoskeletal</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Arthralgia, arthrosis, myalgia, synovitis, tendinitis</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Platelets (bleeding or clotting)</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Ecchymosis, epistaxis, thrombocythemia</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Psychiatric</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Anorexia, anxiety, appetite increased, depression, nervousness, somnolence</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Hemic</content><BR>                                          <content styleCode="italics">: </content><BR>                                       </td><BR>                                       <td>Anemia</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Respiratory</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Bronchitis, bronchospasm, bronchospasm aggravated, coughing, dyspnea, laryngitis, pneumonia</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Skin and appendages</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Alopecia, dermatitis, photosensitivity reaction, pruritus, rash erythematous, rash maculopapular, skin disorder, skin dry, sweating increased, urticaria</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Application site disorders</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Cellulitis, dermatitis contact</td><BR>                                    </tr><BR>                                    <tr styleCode="Botrule"><BR>                                       <td><BR>                                          <content styleCode="bold italics">Urinary</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Albuminuria, cystitis, dysuria, hematuria, micturition frequency, renal calculus</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                           <BR><BR><BR><BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 The following serious adverse events (causality not evaluated) occurred in <0.1% of patients (cases reported only in post-marketing experience are indicated in italics):<BR>                              <BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%" ID="i2cfb84f4-c8a2-4a13-86a4-46407ac275b4"><BR>                                 <col align="left" valign="top" width="25%"/><BR>                                 <col align="left" valign="top" width="75%"/><BR>                                 <tbody><BR>                                    <tr styleCode="toprule"><BR>                                       <td><BR>                                          <content styleCode="bold italics">Cardiovascular</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Syncope, congestive heart failure, ventricular fibrillation, pulmonary embolism, cerebrovascular accident, peripheral gangrene, thrombophlebitis, <content styleCode="italics">vasculitis, deep venous thrombosis</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Gastrointestinal</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Intestinal obstruction, intestinal perforation, gastrointestinal bleeding, colitis with bleeding, esophageal perforation, pancreatitis, ileus</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Liver and biliary</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Cholelithiasis, <content styleCode="italics">hepatitis, jaundice, liver failure</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Hemic and lymphatic</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Thrombocytopenia, <content styleCode="italics">agranulocytosis,aplastic anemia, pancytopenia, leucopenia</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Metabolic:</content><BR>                                       </td><BR>                                       <td><BR>                                          <content styleCode="italics">Hypoglycemia, hyponatremia</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Nervous</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Ataxia, suicide,<content styleCode="italics"> aseptic meningitis, ageusia, anosmia, fatal intracranial hemorrhage [see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Renal</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Acute renal failure,<content styleCode="italics"> interstitial nephritis</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Skin:</content><BR>                                       </td><BR>                                       <td><BR>                                          <content styleCode="italics">Erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis drug rash with eosinophilia and systemic symptoms (DRESS, or hypersensitivity syndrome)</content><BR>                                       </td><BR>                                    </tr><BR>                                    <tr styleCode="botrule"><BR>                                       <td><BR>                                          <content styleCode="bold italics">General</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Sepsis, sudden death, <content styleCode="italics">anaphylactoid reaction, angioedema</content><BR>                                       </td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                           <BR><BR><BR><BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.2 The Celecoxib Long-Term Arthritis Safety Study  <BR>                     <BR>                        <BR>                           [see <BR>                                 Special Studies (14.6)<BR>                              ]<BR>                        <BR>                     <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Hematological Events<BR>                                 : The incidence of clinically significant decreases in hemoglobin (>2 g/dL) was lower in patients on CELEBREX 400 mg twice daily (0.5%) compared to patients on either diclofenac 75 mg twice daily (1.3%) or ibuprofen 800 mg three times daily 1.9%. The lower incidence of events with CELEBREX was maintained with or without ASA use [see Clinical Pharmacology (12.2)<BR>                                 ].<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Withdrawals/Serious Adverse Events<BR>                                 : Kaplan-Meier cumulative rates at 9 months for withdrawals due to adverse events for CELEBREX, diclofenac and ibuprofen were 24%, 29%, and 26%, respectively. Rates for serious adverse events (i.e., causing hospitalization or felt to be life-threatening or otherwise medically significant), regardless of causality, were not different across treatment groups (8%, 7%, and 8%, respectively).<BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.3 Juvenile Rheumatoid Arthritis Study<BR>                     <BR>                        In a 12-week, double-blind, active-controlled study, 242 JRA patients 2 years to 17 years of age were treated with celecoxib or naproxen; 77 JRA patients were treated with celecoxib 3 mg/kg BID, 82 patients were treated with celecoxib 6 mg/kg BID, and 83 patients were treated with naproxen 7.5 mg/kg BID. The most commonly occurring (≥5%) adverse events in celecoxib treated patients were headache, fever (pyrexia), upper abdominal pain, cough, nasopharyngitis, abdominal pain, nausea, arthralgia, diarrhea and vomiting. The most commonly occurring (≥5%) adverse experiences for naproxen-treated patients were headache, nausea, vomiting, fever, upper abdominal pain, diarrhea, cough, abdominal pain, and dizziness (Table 2). Compared with naproxen, celecoxib at doses of 3 and 6 mg/kg BID had no observable deleterious effect on growth and development during the course of the 12-week double-blind study. There was no substantial difference in the number of clinical exacerbations of uveitis or systemic features of JRA among treatment groups.<BR>                        In a 12-week, open-label extension of the double-blind study described above, 202 JRA patients were treated with celecoxib 6 mg/kg BID.  The incidence of adverse events was similar to that observed during the double-blind study; no unexpected adverse events of clinical importance emerged.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="table2" width="80%"><BR>                           <caption>Table 2: Adverse Events Occurring in &#8805;5% of JRA Patients in Any Treatment Group, by System Organ Class (% of patients with events)</caption><BR>                           <col align="left" valign="bottom" width="40%"/><BR>                           <col align="center" valign="bottom" width="20%"/><BR>                           <col align="center" valign="bottom" width="20%"/><BR>                           <col align="center" valign="bottom" width="20%"/><BR>                           <thead><BR>                              <tr><BR>                                 <th/><BR>                                 <th colspan="3" styleCode="Botrule">All  Doses Twice Daily</th><BR>                              </tr><BR>                              <tr><BR>                                 <th>System Organ Class<br/>&#160;&#160;Preferred Term</th><BR>                                 <th>Celecoxib<br/>3 mg/kg<br/>N=77</th><BR>                                 <th>Celecoxib<br/>6 mg/kg<br/>N=82</th><BR>                                 <th>Naproxen<br/>7.5 mg/kg<br/>N=83</th><BR>                              </tr><BR>                           </thead><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td><BR>                                    <content styleCode="bold">Any Event</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">64</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">70</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">72</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td><BR>                                    <content styleCode="bold">Eye Disorders</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">5</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">5</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">5</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td><BR>                                    <content styleCode="bold">Gastrointestinal</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">26</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">24</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">36</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;Abdominal pain NOS</td><BR>                                 <td>4</td><BR>                                 <td>7</td><BR>                                 <td>7</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;Abdominal pain upper</td><BR>                                 <td>8</td><BR>                                 <td>6</td><BR>                                 <td>10</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;Vomiting NOS</td><BR>                                 <td>3</td><BR>                                 <td>6</td><BR>                                 <td>11</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;Diarrhea NOS</td><BR>                                 <td>5</td><BR>                                 <td>4</td><BR>                                 <td>8</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;Nausea</td><BR>                                 <td>7</td><BR>                                 <td>4</td><BR>                                 <td>11</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Toprule"><BR>                                    <content styleCode="bold">General</content><BR>                                 </td><BR>                                 <td styleCode="Toprule"><BR>                                    <content styleCode="bold">13</content><BR>                                 </td><BR>                                 <td styleCode="Toprule"><BR>                                    <content styleCode="bold">11</content><BR>                                 </td><BR>                                 <td styleCode="Toprule"><BR>                                    <content styleCode="bold">18</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td>&#160;&#160;Pyrexia</td><BR>                                 <td>8</td><BR>                                 <td>9</td><BR>                                 <td>11</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td><BR>                                    <content styleCode="bold">Infections </content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">25</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">20</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">27</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td>&#160;&#160;Nasopharyngitis</td><BR>                                 <td>5</td><BR>                                 <td>6</td><BR>                                 <td>5</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td><BR>                                    <content styleCode="bold">Injury and Poisoning </content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">4</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">6</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">5</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td><BR>                                    <content styleCode="bold">Investigations<footnote>Abnormal laboratory tests, which include:  Prolonged activated partial thromboplastin time, Bacteriuria NOS present, Blood creatine phosphokinase increased, Blood culture positive, Blood glucose increased, Blood pressure increased, Blood uric acid increased, Hematocrit decreased, Hematuria present, Hemoglobin decreased, Liver function tests NOS abnormal, Proteinuria present, Transaminase NOS increased, Urine analysis abnormal NOS</footnote><BR>                                    </content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">3</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">11</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">7</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td><BR>                                    <content styleCode="bold">Musculoskeletal </content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">8</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">10</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">17</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td>&#160;&#160;Arthralgia</td><BR>                                 <td>3</td><BR>                                 <td>7</td><BR>                                 <td>4</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td><BR>                                    <content styleCode="bold">Nervous System</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">17</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">11</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">21</content><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;Headache  NOS</td><BR>                                 <td>13</td><BR>                                 <td>10</td><BR>                                 <td>16</td><BR>                              </tr><BR>                              <tr><BR>                                 <td>&#160;&#160;Dizziness  (excl vertigo) </td><BR>                                 <td>1</td><BR>                                 <td>1</td><BR>                                 <td>7</td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td styleCode="Toprule"><BR>                                    <content styleCode="bold">Respiratory</content><BR>                                 </td><BR>                                 <td styleCode="Toprule"><BR>                                    <content styleCode="bold">8</content><BR>                                 </td><BR>                                 <td styleCode="Toprule"><BR>                                    <content styleCode="bold">15</content><BR>                                 </td><BR>                                 <td styleCode="Toprule"><BR>                                    <content styleCode="bold">15</content><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td>&#160;&#160;Cough</td><BR>                                 <td>7</td><BR>                                 <td>7</td><BR>                                 <td>8</td><BR>                              </tr><BR>                              <tr><BR>                                 <td><BR>                                    <content styleCode="bold">Skin &amp; Subcutaneous</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">10</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">7</content><BR>                                 </td><BR>                                 <td><BR>                                    <content styleCode="bold">18</content><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.4 Other Pre-Approval Studies<BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Adverse Events from Ankylosing Spondylitis Studies: A total of 378 patients were treated with CELEBREX in placebo- and active-controlled AS studies. Doses up to 400 mg once daily were studied. The types of adverse events reported in the AS studies were similar to those reported in the OA/RAstudies.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 Adverse Events from Analgesia and Dysmenorrhea Studies: Approximately 1,700 patients were treated with CELEBREX in analgesia and dysmenorrhea studies. All patients in post-oral surgery pain studies received a single dose of study medication. Doses up to 600 mg/day of CELEBREX were studied in primary dysmenorrhea and post-orthopedic surgery pain studies. The types of adverse events in the analgesia and dysmenorrhea studies were similar to those reported in arthritis studies. The only additional adverse event reported was post-dental extraction alveolar osteitis (dry socket) in the post-oral surgery pain studies.<BR>                           <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.5 The APC and PreSAP Trials<BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              <BR>                                 												Adverse reactions from long-term, placebo-controlled polyp prevention studies: Exposure to CELEBREX in the APC and PreSAP trials was 400 to 800 mg daily for up to 3 years [see Special Studies Adenomatous Polyp Prevention Studies (14.6)<BR>                                 ]. <BR>                              Some adverse reactions occurred in higher percentages of patients than in the arthritis pre-marketing trials (treatment durations up to 12 weeks; see <BR>                                    Adverse events from CELEBREX pre-marketing controlled arthritis trials<BR>                                 , above). The adverse reactions for which these differences in patients treated with CELEBREX were greater as compared to the arthritis pre-marketing trials were as follows:  <BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%" ID="i38e24da2-d676-441b-84f4-f083b66738b9"><BR>                                 <col align="left" valign="middle" width="50%"/><BR>                                 <col align="center" valign="middle" width="25%"/><BR>                                 <col align="center" valign="bottom" width="25%"/><BR>                                 <thead><BR>                                    <tr><BR>                                       <th/><BR>                                       <th>CELEBREX<br/>(400 to 800 mg daily)<br/>N = 2285</th><BR>                                       <th>Placebo<br/>N=1303</th><BR>                                    </tr><BR>                                 </thead><BR>                                 <tbody><BR>                                    <tr><BR>                                       <td>Diarrhea</td><BR>                                       <td>10.5%</td><BR>                                       <td>7.0%</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td>Gastroesophageal reflux disease</td><BR>                                       <td>4.7%</td><BR>                                       <td>3.1%</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td>Nausea</td><BR>                                       <td>6.8%</td><BR>                                       <td>5.3%</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td>Vomiting</td><BR>                                       <td>3.2%</td><BR>                                       <td>2.1%</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td>Dyspnea</td><BR>                                       <td>2.8%</td><BR>                                       <td>1.6%</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td>Hypertension</td><BR>                                       <td>12.5%</td><BR>                                       <td>9.8%</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                           <BR><BR><BR><BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           <BR>                           <BR>                           <BR>                              The following additional adverse reactions occurred in ≥0.1% and <1% of patients taking CELEBREX, at an incidence greater than placebo in the long-term polyp prevention studies and were either not reported during the controlled arthritis pre-marketing trials or occurred with greater frequency in the long-term, placebo-controlled polyp prevention studies:<BR>                              <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="80%" ID="i9d25c116-9a7f-4490-8477-ef498434b6f6"><BR>                                 <col align="left" valign="top" width="25%"/><BR>                                 <col align="left" valign="top" width="75%"/><BR>                                 <tbody><BR>                                    <tr styleCode="toprule"><BR>                                       <td><BR>                                          <content styleCode="bold italics">Nervous system disorders:</content><BR>                                       </td><BR>                                       <td>Cerebral infarction</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Eye disorders</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Vitreous floaters, conjunctival hemorrhage</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Ear and labyrinth</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Labyrinthitis</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Cardiac disorders</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Angina unstable, aortic valve incompetence, coronary artery atherosclerosis, sinus bradycardia, ventricular hypertrophy</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Vascular disorders</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Deep vein thrombosis</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Reproductive system and breast disorders</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Ovarian cyst</td><BR>                                    </tr><BR>                                    <tr><BR>                                       <td><BR>                                          <content styleCode="bold italics">Investigations</content><BR>                                          <content styleCode="italics">:</content><BR>                                       </td><BR>                                       <td>Blood potassium increased, blood sodium increased, blood testosterone decreased</td><BR>                                    </tr><BR>                                    <tr styleCode="botrule"><BR>                                       <td><BR>                                          <content styleCode="bold italics">Injury, poisoning and procedural complications:</content><BR>                                       </td><BR>                                       <td>Epicondylitis, tendon rupture</td><BR>                                    </tr><BR>                                 </tbody><BR>                              </table><BR>                           <BR><BR><BR><BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>